264 related articles for article (PubMed ID: 33029257)
1. Relationship between Plasma Lipoprotein-Associated Phospholipase A2 Concentrations and Apolipoprotein in Stable Coronary Artery Disease Patients.
Ling Y; Tang S; Cao Y; Fu C
Dis Markers; 2020; 2020():8818358. PubMed ID: 33029257
[TBL] [Abstract][Full Text] [Related]
2. Relationship between plasma phospholipase A2 concentrations and lipoprotein subfractions in patients with stable coronary artery disease.
Xu RX; Zhang Y; Li XL; Li S; Guo YL; Dong Q; Liu G; Li JJ
Clin Chim Acta; 2015 Jun; 446():195-200. PubMed ID: 25934512
[TBL] [Abstract][Full Text] [Related]
3. Increased serum level of Lp-PLA2 is independently associated with the severity of coronary artery diseases: a cross-sectional study of Chinese population.
Cai A; Li G; Chen J; Li X; Li L; Zhou Y
BMC Cardiovasc Disord; 2015 Feb; 15():14. PubMed ID: 25879827
[TBL] [Abstract][Full Text] [Related]
4. The relationship of lipoprotein-associated phospholipase A2 activity with the seriousness of coronary artery disease.
Zhang H; Gao Y; Wu D; Zhang D
BMC Cardiovasc Disord; 2020 Jun; 20(1):295. PubMed ID: 32546193
[TBL] [Abstract][Full Text] [Related]
5. Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study.
Kiechl S; Willeit J; Mayr M; Viehweider B; Oberhollenzer M; Kronenberg F; Wiedermann CJ; Oberthaler S; Xu Q; Witztum JL; Tsimikas S
Arterioscler Thromb Vasc Biol; 2007 Aug; 27(8):1788-95. PubMed ID: 17541022
[TBL] [Abstract][Full Text] [Related]
6. Interpretation of lipoprotein-associated phospholipase A2 levels is influenced by cardiac disease, comorbidities, extension of atherosclerosis and treatments.
Charniot JC; Khani-Bittar R; Albertini JP; Giral P; Cherfils C; Cosson C; Guillerm E; Leprince P; Gandjbakhch I; Bonnefont-Rousselot D
Int J Cardiol; 2013 Sep; 168(1):132-8. PubMed ID: 23103135
[TBL] [Abstract][Full Text] [Related]
7. Lipoprotein-associated phospholipase A2 levels, endothelial dysfunction and arterial stiffness in patients with stable coronary artery disease.
Mourouzis K; Siasos G; Oikonomou E; Zaromitidou M; Tsigkou V; Antonopoulos A; Bletsa E; Stampouloglou P; Vlasis K; Vavuranakis M; Tousoulis D
Lipids Health Dis; 2021 Feb; 20(1):12. PubMed ID: 33583415
[TBL] [Abstract][Full Text] [Related]
8. Relationship of lipoprotein-associated apolipoprotein C-III with lipid variables and coronary artery disease risk: The EPIC-Norfolk prospective population study.
van Capelleveen JC; Lee SR; Verbeek R; Kastelein JJP; Wareham NJ; Stroes ESG; Hovingh GK; Khaw KT; Boekholdt SM; Witztum JL; Tsimikas S
J Clin Lipidol; 2018; 12(6):1493-1501.e11. PubMed ID: 30249512
[TBL] [Abstract][Full Text] [Related]
9. Association of 25-hydroxyvitamin D, lipoprotein-associated phospholipase A2 and asymptomatic coronary artery disease in patients with type 2 diabetes mellitus.
Zhang Q; Zhang QQ; He JJ; Dong SQ; Lu Y
Diabetes Res Clin Pract; 2024 Jun; 212():111681. PubMed ID: 38677367
[TBL] [Abstract][Full Text] [Related]
10. The role of Lp-PLA
Sairam SG; Sola S; Barooah A; Javvaji SK; Jaipuria J; Venkateshan V; Chelli J; Sanjeevi CB
Cardiovasc Diagn Ther; 2017 Dec; 7(6):589-597. PubMed ID: 29302464
[TBL] [Abstract][Full Text] [Related]
11. Association of Lp-PLA2 with digital reactive hyperemia, coronary flow reserve, carotid atherosclerosis and arterial stiffness in coronary artery disease.
Ikonomidis I; Kadoglou NN; Tritakis V; Paraskevaidis I; Dimas K; Trivilou P; Papadakis I; Tzortzis S; Triantafyllidi H; Parissis J; Anastasiou-Nana M; Lekakis J
Atherosclerosis; 2014 May; 234(1):34-41. PubMed ID: 24594367
[TBL] [Abstract][Full Text] [Related]
12. Oxidation-specific biomarkers, lipoprotein(a), and risk of fatal and nonfatal coronary events.
Tsimikas S; Mallat Z; Talmud PJ; Kastelein JJ; Wareham NJ; Sandhu MS; Miller ER; Benessiano J; Tedgui A; Witztum JL; Khaw KT; Boekholdt SM
J Am Coll Cardiol; 2010 Sep; 56(12):946-55. PubMed ID: 20828647
[TBL] [Abstract][Full Text] [Related]
13. Lipoprotein-associated phospholipase A₂ activity is increased in patients with definite familial hypercholesterolemia compared with other forms of hypercholesterolemia.
Mattina A; Rosenbaum D; Bittar R; Bonnefont-Rousselot D; Noto D; Averna M; Bruckert E; Giral P
Nutr Metab Cardiovasc Dis; 2018 May; 28(5):517-523. PubMed ID: 29525223
[TBL] [Abstract][Full Text] [Related]
14. Association between Lp-PLA2 and coronary artery disease: focus on its relationship with lipoproteins and markers of inflammation and hemostasis.
Khuseyinova N; Imhof A; Rothenbacher D; Trischler G; Kuelb S; Scharnagl H; Maerz W; Brenner H; Koenig W
Atherosclerosis; 2005 Sep; 182(1):181-8. PubMed ID: 16115490
[TBL] [Abstract][Full Text] [Related]
15. Lipoprotein-associated phospholipase A2 and risk of incident cardiovascular disease in a multi-ethnic cohort: The multi ethnic study of atherosclerosis.
Garg PK; McClelland RL; Jenny NS; Criqui MH; Greenland P; Rosenson RS; Siscovick DS; Jorgensen N; Cushman M
Atherosclerosis; 2015 Jul; 241(1):176-82. PubMed ID: 26004387
[TBL] [Abstract][Full Text] [Related]
16. Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) in acute coronary syndrome: relationship with low-density lipoprotein cholesterol.
Jabor B; Choi H; Ruel I; Hafiane A; Mourad W; Genest J
Can J Cardiol; 2013 Dec; 29(12):1679-86. PubMed ID: 24267807
[TBL] [Abstract][Full Text] [Related]
17. Prognostic utility of lipoprotein-associated phospholipase A2 for cardiovascular outcomes in patients with stable coronary artery disease.
Sabatine MS; Morrow DA; O'Donoghue M; Jablonksi KA; Rice MM; Solomon S; Rosenberg Y; Domanski MJ; Hsia J;
Arterioscler Thromb Vasc Biol; 2007 Nov; 27(11):2463-9. PubMed ID: 17766330
[TBL] [Abstract][Full Text] [Related]
18. Increased plasma lipoprotein-associated phospholipase A2 levels are associated with coronary slow flow.
Ding YD; Pei YQ; Wang R; Yang JX; Zhao YX; Liu XL; Shen H; Ma Q; Zhang S; Ge HL
BMC Cardiovasc Disord; 2020 May; 20(1):248. PubMed ID: 32460702
[TBL] [Abstract][Full Text] [Related]
19. Lipoprotein-Associated Phospholipase A2 in Cardiac Disease: a Potential Early Biomarker of Unstable Coronary Artery Disease.
Li J; Zhou Z; Niu X; Li H
Clin Lab; 2020 May; 66(5):. PubMed ID: 32390386
[TBL] [Abstract][Full Text] [Related]
20. Circulating growth differentiation factor 15 levels and apolipoprotein B to apolipoprotein A1 ratio in coronary artery disease patients with type 2 diabetes mellitus.
Mei Y; Zhao Z; Lyu Y; Li Y
Lipids Health Dis; 2022 Jul; 21(1):59. PubMed ID: 35842724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
